Cue Biopharma is trading 9.6% up at $40.01 in pre-market after announcing a $50 million private placement of common stock and pre-funded warrants to institutional investors.
- The financing strengthens the company’s balance sheet to support the advancement of its immunology pipeline.
- Pre-market traders are reacting positively to the capital raise terms and the level of institutional participation.